CTT Pharmaceutical Holdings said it has advanced past the initial round in its application for a National Science Foundation (NSF) grant for its patented fast-dissolving nicotine strips. The company is now among a few thousand remaining applicants from an initial pool of over 12,000 applicants. Acceptance into the program would give CTT government backing and allow for extensive research and testing to help in the development of its technology.
“To make it past the first round of applicants is a huge accomplishment by itself and shows that the NSF sees potential value for our technology within the tobacco industry,” said Ryan Khouri, CEO of CTT Pharma. “Currently there are no fast-dissolving, low-dose nicotine strips on the market, as most oral products stay in the mouth for an excessive amount of time.”
The company’s technology aims to address a significant public health issue, as classified by WHO. CTT said it expects to receive a response by late April.